Abstract

The hexanucleotide repeat mutation in the intron-1 of the chromosome 9 open reading frame (C9orf72) is a frequent cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Altered RNA folding plays a role in ALS pathogenesis in two ways: non-ATG translation of the repeat can lead to aggregates of the known C9orf72 specific dipeptide polymer, whereas the repeat also can form neurotoxic RNA inclusions that dose-responsively kill motor neurons. We report the presence of a homology in the 5’untranslated region (UTR) of the messenger RNA encoding C9orf72 with the iron responsive elements (IRE) that control expression of iron-associated transcripts and predict that this RNA structure may iron-dependently regulate C9orf72 translation. We previously report altered serum ferritin levels track with severity of ALS in patients. Here, we conduct bioinformatics analyses to determine the secondary structure of the 5’UTR in C9orf72 mRNA and find it aligned with IREs in the human mitochondrial cis-aconitase and L and H-ferritin transcripts. Comparison of the role of RNA repeats in Friedriech’s ataxia and fragile X mental retardation suggests the utility of RNA based therapies for treatment of ALS. Antisense oligonucleotides (ASO) have been reported to therapeutically target these GGGGCC repeats. At the same time, because the function of C9orf72 is unknown, knockdown strategies carry some risk of inducing or compounding haploinsufficiency. We propose, for consideration, an approach that may enhance its therapeutic dynamic range by increasing the 5’UTR driven translation of C9orf72 protein to compensate for any potential ALS-specific or ASO-induced haploinsufficieny.

Highlights

  • Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are both devastating neurological diseases

  • We conducted bioinformatics sequence comparisons and RNA secondary structure predictions to determine the secondary structure of the 5’untranslated region (UTR) of the transcript encoding C9orf72 relative to the iron responsive elements (IRE) encoded by mitochondrial aconitase, H-ferritin, and L-ferritin messenger RNA (mRNA)

  • We propose novel small molecule therapies for ALS and FTD based on the strategy of screening and identifying small molecules to activate translation of the specific IRE-like RNA stem loop in 5’UTR of C9orf72 mRNA to enhance its translation in front of the start codon

Read more

Summary

Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are both devastating neurological diseases. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder causing weakness, as well as other symptoms mediated by loss of upper and lower motor neurons. Lower motor neuron degeneration results in fasciculations and muscle atrophy, and upper motor neuron degeneration result in increased reflexes and spasticity. ALS is usually fatal due to respiratory paralysis within 1 to 5 years of symptom onset. The average age of onset is 55 to 65 years old and prevalence of ALS is 3 to 5/100,000 [1]. Frontotemporal dementia (FTD) is the second most common cause of pre-senile dementia after Alzheimer’s disease, with the mean age of onset in the fifth to seventh decades of life [2]. Degeneration of the frontal and temporal lobes of the brain lead to progressive changes in behavior, personality and language

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call